ACP Letter to FDA Regarding Revisions to Policies for Compounding of Allergen Extracts

Letter to the Food and Drug Administration urging careful consideration of the safety record associated with sterile preparation of allergen extracts and negative impact on patient access that may be associated with elimination of the current in-office compounding procedures.

allergen immunotherapy, AIT, FDA, Food and Drug Administration,Compounded Sterile Preparations, CSP, pharmaceutical compounding, US Pharmacopeial Convention, USP

Mon, 07/18/2016 - 10:23 AM EDT

Tue, 07/19/2016 - 9:41 AM EDT

3

letter_fda_compounding_allergen_extracts_2016.pdf

{"CreationDate":"2016-07-18T10:23:23-04:00","Creator":"Microsoft\u00ae Word 2010","Keywords":"allergen immunotherapy, AIT, FDA, Food and Drug Administration,Compounded Sterile Preparations, CSP, pharmaceutical compounding, US Pharmacopeial Convention, USP","ModDate":"2016-07-19T09:41:25-04:00","Producer":"Microsoft\u00ae Word 2010","Title":"ACP Letter to FDA Regarding Revisions to Policies for Compounding of Allergen Extracts ","Pages":3,"dc:format":"application\/pdf","dc:creator":"","dc:title":"ACP Letter to FDA Regarding Revisions to Policies for Compounding of Allergen Extracts ","dc:subject":["allergen immunotherapy","AIT","FDA","Food and Drug Administration","Compounded Sterile Preparations","CSP","pharmaceutical compounding","US Pharmacopeial Convention","USP"],"xmp:createdate":"2016-07-18T10:23:23-04:00","xmp:creatortool":"Microsoft\u00ae Word 2010","xmp:modifydate":"2016-07-19T09:41:25-04:00","xmp:metadatadate":"2016-07-19T09:41:25-04:00","pdf:producer":"Microsoft\u00ae Word 2010","pdf:keywords":"allergen immunotherapy, AIT, FDA, Food and Drug Administration,Compounded Sterile Preparations, CSP, pharmaceutical compounding, US Pharmacopeial Convention, USP","xmpmm:documentid":"uuid:30103931-768e-4184-8745-9016247c2c11","xmpmm:instanceid":"uuid:cb839260-16ec-4807-9f89-b626c2d868ec"}

2016